Safety and Efficacy of Frexalimab in Relapsing Multiple Sclerosis: 48-week Results from the Phase 2 Open-label Extension (S31.007)Gavin Giovannoni,Cristina Granziera,Yang Mao-Draayer,Gary Cutter, Oleksandr Kalbus, Ivan Staikov,Michal Dufek,Stephane Saubadu,Raphael Bejuit, Biljana Djukic,Philippe Truffinet,Erik Wallstroem,Patrick VermerschNeurology(2024)引用 0|浏览5暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要